Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HBIO 
Harvard Bioscience Inc (HBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: HBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.39% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.78M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 2 | Beta 1.52 | 52 Weeks Range 0.28 - 2.82 | Updated Date 10/13/2025 |
52 Weeks Range 0.28 - 2.82 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -64.68% | Operating Margin (TTM) -3.03% |
Management Effectiveness
Return on Assets (TTM) -1.98% | Return on Equity (TTM) -138.36% |
Valuation
Trailing PE - | Forward PE 14.93 | Enterprise Value 56325179 | Price to Sales(TTM) 0.21 |
Enterprise Value 56325179 | Price to Sales(TTM) 0.21 | ||
Enterprise Value to Revenue 0.63 | Enterprise Value to EBITDA 179.26 | Shares Outstanding 44531198 | Shares Floating 33721250 |
Shares Outstanding 44531198 | Shares Floating 33721250 | ||
Percent Insiders 10.32 | Percent Institutions 54.95 |
Upturn AI SWOT
Harvard Bioscience Inc
Company Overview
History and Background
Harvard Bioscience, Inc. (HBIO) was founded in 1901. It provides tools and technologies to advance life science research and regenerative medicine. Initially focused on manufacturing physiological instruments, it has evolved through acquisitions and organic growth.
Core Business Areas
- Cellular & Molecular Technologies: This segment focuses on products used in cell culture, sample preparation, and molecular analysis. It includes products like electrophoresis systems, centrifuges, and pipettes.
- Physiology Systems: This segment develops and manufactures instruments for physiology research, including data acquisition systems, transducers, and software for studying organ systems and animal behavior.
- Preclinical Solutions: Provides equipment used in drug discovery and preclinical testing, like surgical instruments, ventilators, and monitoring systems for small animals.
Leadership and Structure
The leadership team is headed by the CEO, who oversees the executive team. The organizational structure consists of functional departments such as R&D, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Data Acquisition Systems: These systems are used to collect physiological data in real-time. Market share information is not publicly disclosed for specific products, but the data acquisition market is competitive. Competitors include ADInstruments and DSI (Data Sciences International).
- Syringe Pumps: Harvard Bioscience is known for its precision syringe pumps used in research and drug delivery. Market share information is not publicly disclosed. Competitors include Cole-Parmer and KD Scientific.
- Cellular Electroporation Systems: Used for introducing foreign substances into cells. Market share information is not publicly disclosed. Competitors include BTX Harvard Apparatus and Lonza.
Market Dynamics
Industry Overview
The life science tools market is driven by increasing research funding, advancements in biotechnology, and growing demand for personalized medicine. The market is highly competitive and fragmented.
Positioning
Harvard Bioscience occupies a niche position by providing specialized instruments and tools for specific research applications. Its competitive advantage lies in its established brand and reputation for quality.
Total Addressable Market (TAM)
The global life science tools market is estimated to be worth hundreds of billions of dollars annually. Harvard Bioscience is positioned to capture a portion of this market with its niche offerings.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Established customer base
- Specialized product portfolio
- Global presence
Weaknesses
- Smaller size compared to major competitors
- Limited R&D budget compared to larger companies
- Dependence on grant funding for research
- Relatively low market capitalization
Opportunities
- Expanding into emerging markets
- Developing new products for regenerative medicine
- Strategic acquisitions of complementary businesses
- Partnerships with pharmaceutical companies
Threats
- Increased competition from larger players
- Economic downturn affecting research funding
- Technological disruption
- Regulatory changes
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Agilent Technologies (A)
Competitive Landscape
Harvard Bioscience is smaller than its major competitors. It focuses on niche markets, while competitors such as Thermo Fisher Scientific offer a wider range of products.
Major Acquisitions
Data Sciences International (DSI)
- Year: 2018
- Acquisition Price (USD millions): 70
- Strategic Rationale: Expanded product offerings in preclinical research and enhanced presence in the data acquisition market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been moderate, with fluctuations due to economic conditions and acquisition activity.
Future Projections: Analyst estimates vary, with projections dependent on successful product launches and market expansion.
Recent Initiatives: Recent initiatives include streamlining operations, focusing on core products, and expanding into new markets.
Summary
Harvard Bioscience has a strong brand but faces challenges competing with larger companies. Its focus on specialized products provides a niche, but it must continue to innovate. The company needs to improve its financial performance and shareholder value, while facing external economic and competitive pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Market Research Reports
- Analyst Estimates
- Company Website
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share and financial data are estimates and may not be precise. Always conduct thorough due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harvard Bioscience Inc
Exchange NASDAQ | Headquaters Holliston, MA, United States | ||
IPO Launch date 2000-12-07 | President, CEO & Director Mr. John Duke | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 330 | |
Full time employees 330 | |||
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.